A Promising Future for Prostate Cancer Diagnostics
It has been estimated that globally there is a death attributable to prostate cancer every four minutes. As life expectancy in all world regions increases, so too incidence of this disease of the ageing male will increase. For many men diagnosis occurs after presentation with symptoms of altered uri...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-01-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | http://www.mdpi.com/2075-4418/7/1/6 |
id |
doaj-cac273cd03b2474398b7c47ec09c7429 |
---|---|
record_format |
Article |
spelling |
doaj-cac273cd03b2474398b7c47ec09c74292020-11-24T22:19:30ZengMDPI AGDiagnostics2075-44182017-01-0171610.3390/diagnostics7010006diagnostics7010006A Promising Future for Prostate Cancer DiagnosticsStephen J. Assinder0Vanitha Bhoopalan1Discipline of Physiology, School of Biomedical Sciences and Bosch Institute, University of Sydney, Sydney, NSW 2006, AustraliaDiscipline of Physiology, School of Biomedical Sciences and Bosch Institute, University of Sydney, Sydney, NSW 2006, AustraliaIt has been estimated that globally there is a death attributable to prostate cancer every four minutes. As life expectancy in all world regions increases, so too incidence of this disease of the ageing male will increase. For many men diagnosis occurs after presentation with symptoms of altered urinary dynamics. Unfortunately, these changes, whilst also associated with benign disease, are evident quite late in the aetiology of prostate cancer. Early detection provides for better management and prognosis. This Special Issue provides an up to date view of the advances made towards early diagnosis and prognosis. It provides reviews of advanced imaging techniques (e.g., multiparametric MRI and protocols), and of biomaterials and molecular biomarkers currently being explored (e.g., microRNAs, proteomics) and the technologies that are revolutionizing this field. It describes the multi-disciplinary approaches that are essential to inexpensive, deliverable and accurate platforms for prostate cancer diagnostics.http://www.mdpi.com/2075-4418/7/1/6PI-RADSdiffusion weighted imaging223RaCl2[18F]-NaF PET/CTPERCISTcirculating tumour cellsoncosomesoncosomal DNAs and RNAsquantum dot multiplex arrayscarbon nanotube technologies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stephen J. Assinder Vanitha Bhoopalan |
spellingShingle |
Stephen J. Assinder Vanitha Bhoopalan A Promising Future for Prostate Cancer Diagnostics Diagnostics PI-RADS diffusion weighted imaging 223RaCl2 [18F]-NaF PET/CT PERCIST circulating tumour cells oncosomes oncosomal DNAs and RNAs quantum dot multiplex arrays carbon nanotube technologies |
author_facet |
Stephen J. Assinder Vanitha Bhoopalan |
author_sort |
Stephen J. Assinder |
title |
A Promising Future for Prostate Cancer Diagnostics |
title_short |
A Promising Future for Prostate Cancer Diagnostics |
title_full |
A Promising Future for Prostate Cancer Diagnostics |
title_fullStr |
A Promising Future for Prostate Cancer Diagnostics |
title_full_unstemmed |
A Promising Future for Prostate Cancer Diagnostics |
title_sort |
promising future for prostate cancer diagnostics |
publisher |
MDPI AG |
series |
Diagnostics |
issn |
2075-4418 |
publishDate |
2017-01-01 |
description |
It has been estimated that globally there is a death attributable to prostate cancer every four minutes. As life expectancy in all world regions increases, so too incidence of this disease of the ageing male will increase. For many men diagnosis occurs after presentation with symptoms of altered urinary dynamics. Unfortunately, these changes, whilst also associated with benign disease, are evident quite late in the aetiology of prostate cancer. Early detection provides for better management and prognosis. This Special Issue provides an up to date view of the advances made towards early diagnosis and prognosis. It provides reviews of advanced imaging techniques (e.g., multiparametric MRI and protocols), and of biomaterials and molecular biomarkers currently being explored (e.g., microRNAs, proteomics) and the technologies that are revolutionizing this field. It describes the multi-disciplinary approaches that are essential to inexpensive, deliverable and accurate platforms for prostate cancer diagnostics. |
topic |
PI-RADS diffusion weighted imaging 223RaCl2 [18F]-NaF PET/CT PERCIST circulating tumour cells oncosomes oncosomal DNAs and RNAs quantum dot multiplex arrays carbon nanotube technologies |
url |
http://www.mdpi.com/2075-4418/7/1/6 |
work_keys_str_mv |
AT stephenjassinder apromisingfutureforprostatecancerdiagnostics AT vanithabhoopalan apromisingfutureforprostatecancerdiagnostics AT stephenjassinder promisingfutureforprostatecancerdiagnostics AT vanithabhoopalan promisingfutureforprostatecancerdiagnostics |
_version_ |
1725778781091659776 |